Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
TKO Group Holdings Q4 2025 Earnings Call - Media rights and FIPs set up step-change to near 40% Adjusted EBITDA margin in 2026
TKO spent 2025 stitching together a playbook: blockbuster media rights, aggressive partnership wins, and a strategy to monetize location subsidies, all of which produce a sharp financial inflection in...
- Media rights are the engine: UFC secured a $7.7 billion deal with Paramount, WWE signed a $1.6 billion deal with ESPN for PLEs, and TKO now has over $15 billion of long-term media rights across UFC, WWE, PBR, and Zuffa Boxing.
- 2026 guidance is a step function: management targets $5.675 billion to $5.775 billion of revenue and $2.24 billion to $2.29 billion of Adjusted EBITDA, implying roughly 21% revenue growth and 43% Adjusted EBITDA growth year over year.
- Margin expansion is explicit and large, management guiding to approximately 39.6% Adjusted EBITDA margin at the midpoint, up about 600 basis points from 2025.
- +16 more takeaways
StandardAero Q4 2025 Earnings Call - LEAP Ramp and Cash Conversion Power Record Year
StandardAero closed 2025 with clear momentum, driven by a rapid LEAP industrialization, robust organic growth across core engine platforms, and a material swing into positive cash generation. Revenue ...
- 2025 was a record year, with total company revenue up 15.8% year over year and Adjusted EBITDA up 17% to $808 million.
- Free cash flow turned positive at $209 million for full-year 2025, with a $308 million quarterly improvement in Q4 driven by delivering engines held up by parts; management reported over $300 million of FCF generated in H2 2025.
- LEAP program ramped materially: 60 LEAP engines inducted in 2025 versus 10 in 2024, with second half 2025 LEAP revenues approximately 2.5 times first half revenues; company has developed more than 475 LEAP component repairs and completed its first full overhaul on the platform.
- +13 more takeaways
Sarepta Therapeutics Fourth Quarter 2025 Earnings Call - ELEVIDYS reset year as company guides $1.2B-$1.4B and CEO to retire
Sarepta entered 2026 with a strengthened balance sheet and a clear, if cautious, roadmap: $954 million in cash, a plan to be non-GAAP profitable and cash flow positive this year, and guidance of $1.2 ...
- Company finished 2025 with $954 million in cash and investments, up $89 million in Q4, and expects to be cash flow positive and non-GAAP profitable in 2026 while continuing pipeline investment.
- Sarepta provided full-year net product revenue guidance for 2026 of $1.2 billion to $1.4 billion for its approved therapies, recommending modelers bias toward the low end given ELEVIDYS timing uncertainty.
- Management labeled 2026 a critical reset year for ELEVIDYS, citing an information deficit after 2025 safety events, and is deploying enhanced educational programs and expanded field teams to rebuild demand.
- +12 more takeaways
Chime Q4 2025 Earnings Call - Chime Core Migration and MyPay Reset Drive Margin Acceleration and 2026 Profit Guidance
Chime closed 2025 with stronger-than-expected results, finishing Q4 with accelerating revenue, margin expansion and the full deployment of its homegrown ledger, Chime Core. Management says Chime Core ...
- Q4 2025 results beat guidance, capping a 2025 year with 31% revenue growth, and Q4 revenue growth of 25% year-over-year.
- Chime completed its multi-year migration to Chime Core, now 100% on its own transaction processor and ledger, which management says reduces transaction processing costs by ~60% and lowers cost to serve to roughly one-third of large banks and one-fifth of regional banks.
- Q4 transaction margin rose to 72% (from 69% in Q3) and management says Chime Core’s final stage delivered a 200 basis point gross margin benefit, supporting a long-term gross margin target of 90%.
- +13 more takeaways
Tucows Q4 2025 Earnings Call - Ting divestiture ongoing, Wavelo EBITDA guided lower on conservative Ting scenarios
Tucows fielded three investor questions emphasizing that the Ting divestiture process is active and not delayed by recent market volatility. Management says timelines are driven by asset specifics and...
- The company answered three investor questions following its Q4 2025 results.
- Ting divestiture process is ongoing, management says it has not been delayed by recent market volatility.
- Management believes external market volatility does not directly impact the Ting timeline; timelines are driven by asset specifics and diligence.
- +10 more takeaways
Maravai LifeSciences Q4 2025 Earnings Call - Restructuring Pays Off, Guiding to EBITDA Positive 2026 on ~$200M Revenue
Maravai closed 2025 with clear evidence the reset is working. Q4 marked the company’s first positive adjusted EBITDA in four quarters, driven by more than $65 million in annualized cost savings, stron...
- Company renamed reporting segments to TriLink (formerly Nucleic Acid Production) and Cygnus (formerly Biologic Safety Testing); nomenclature only, no change in segment composition.
- Full-year 2025 revenue was $185.7 million, beating guidance by about $0.7 million. Q4 revenue was $49.9 million, and excluding $14.3 million of high-volume COVID CleanCap sales in Q4 2024, Q4 revenue grew 18% year-over-year.
- TriLink generated $34.6 million of Q4 revenue, down 17% YoY, but excluding the COVID CleanCap comp, TriLink base revenue grew 25% YoY. TriLink full-year revenue was $119.8 million with adjusted EBITDA of negative $23.1 million.
- +16 more takeaways
Pursuit Q4 & FY 2025 Earnings Call - Record 2025 and Vision 2030: $845M Revenue Target Backed by $300M Pipeline
Pursuit closed 2025 with a clear beat and an ambitious roadmap. Revenue hit a record $452.4 million, up 23% year over year, while Adjusted EBITDA surged to $117.1 million, up 52% and lifting margins t...
- Record full-year 2025 revenue of $452.4 million, up 23% year over year.
- Adjusted EBITDA jumped to $117.1 million, a 52% increase, driving a 500 basis point margin expansion to 26%.
- Guest demand remained robust with 4.2 million attraction visitors and 439,000 room nights in 2025.
- +12 more takeaways
McGrath RentCorp Fourth Quarter 2025 Earnings Call - Smooth CEO Transition and Modular/TRS-Driven 2026 Playbook
Joe Hanna confirmed his retirement effective April 3 and handed the baton to long-time COO Phil Hawkins, signaling continuity rather than a reset. Q4 capped a mixed 2025: revenue up 5% to $257 million...
- CEO succession confirmed: Joe Hanna to retire April 3, 2026, Phil Hawkins named CEO, signaling strategic continuity rather than a directional shift.
- Q4 total revenue $257 million, up 5% year-over-year, with rental operations up 6% and sales revenue up 5%.
- Q4 Adjusted EBITDA $105 million, up 14% year-over-year, driven primarily by Mobile Modular and TRS-RenTelco.
- +12 more takeaways
Sezzle Inc. Q4 2025 Earnings Call - Record profitability and margin expansion, 2026 guide raised
Sezzle closed 2025 with a blowout year: revenue up 66.1% for the year ($450.3M) and a Q4 revenue acceleration of 32.2%, while GAAP net income hit $42.7M in Q4 and $133.1M for the year. The company pus...
- Q4 revenue grew 32.2%, full-year 2025 revenue rose 66.1% to $450.3 million.
- GAAP net income reached $42.7 million in Q4 and full-year net income was $133.1 million; adjusted net income for 2025 was reported near $128.4 million.
- Adjusted EBITDA hit $58.3 million in Q4, a 44.9% margin, and $187.7 million for the full year, showing substantial operating leverage.
- +12 more takeaways
LeMaitre Vascular Q4 2025 Earnings Call - Margin Expansion and Product Launches Set Up 2026 Growth
LeMaitre closed 2025 with a clean quarter: Q4 revenue up 16%, gross margin at 71.7%, and operating income rising 47%, driven by price, manufacturing efficiencies, and product momentum across grafts, v...
- Q4 results: revenue +16% year-over-year, gross margin 71.7%, operating income +47%, Q4 diluted EPS $0.68 (includes $0.05 one-time mark-to-market loss on an investment).
- Full-year 2025: organic revenue +14% (9% price, 5% units), adjusted gross margin 70.4% (up 180 bps vs. 2024), adjusted operating margin 26%, adjusted EPS +23% (excludes Employee Retention Tax Credit benefit).
- 2026 guidance: revenue $280 million, organic growth ~12%, gross margin 72.1%, adjusted operating income $77.8 million (about +21% adjusted), and adjusted EPS $2.91 (+22% adjusted).
- +11 more takeaways